Models for Counts and Particle Size Distributions of Subvisible Particle Data

References

1. 1.↵
   U.S. Food and Drug Administration. Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products. FDA Web site, 2014. https://www.fda.gov/media//85017/ (accessed November 7, 2019).

   Google Scholar
2. 2.↵
   1. Das T. K.

   Protein Particulate Detection Issues in Biotherapeutics Development—Current Status. AAPS PharmSciTech 2012, 13 (2), 732–746.

   OpenUrlCrossRefPubMedGoogle Scholar
3. 3.↵
   1. Narhi L.

   Characterization and Biological Relevance of Protein Aggregates and Other Particles 100–200,000 nm in Size (Sub-Micron and Sub-Visible). CASSS Web site, 2019. https://cdn.ymaws.com/www.casss.org/resource/resmgr/hos_speaker_slides/2019_narhi_linda_slides.pdf (accessed November 7, 2019).

   Google Scholar
4. 4.↵
   1. Collett D.

   Modelling Binary Data, 2nd ed.; CRC Press, Chapman and Hall: London, 2013.

   Google Scholar
5. 5.↵
   1. Stroup W. W.

   Generalized Linear Mixed Models; CRC Press, Chapman and Hall: Boca Raton, Florida, 2013.

   Google Scholar
6. 6.↵
   1. Nath N.,
   2. McNeal E.,
   3. Obenhuber D.,
   4. Pillari B.,
   5. Shelton L.,
   6. Stevens-Riley M.,
   7. Sweeney N.

   Particulate Contaminants of Intravenous Medication and the Limits Set by USP General Chapter <788>. Pharmacopeial Forum 2004, 30 (6), 2272–2280.

   OpenUrlGoogle Scholar
7. 7.↵
   1. Corvari V.,
   2. Narhi L. O.,
   3. Spitznagel T. M.,
   4. Afonina N.,
   5. Cao S.,
   6. Cash P.,
   7. Cecchini I.,
   8. DeFelippis M. R.,
   9. Garidel P.,
   10. Herre A.,
   11. Koulov A. V.,
   12. Lubiniecki T.,
   13. Mahler H.-C.,
   14. Mangiagalli P.,
   15. Nesta D.,
   16. Perez-Ramirez B.,
   17. Polozova A.,
   18. Rossi M.,
   19. Schmidt R.,
   20. Simler R.,
   21. Singh S.,
   22. Weiskopf A.,
   23. Wuchner K.

   Subvisible (2–100 µm) Particle Analysis during Biotherapeutic Drug Product Development: Part 2, Experience with the Application of Subvisible Particle Analysis. Biologicals 2015, 43 (6), 457–473.

   OpenUrlGoogle Scholar
8. 8.↵
   1. Demeule B.,
   2. Messick S.,
   3. Shire S. J.,
   4. Liu J.

   Characterization of Particles in Protein Solutions: Reaching the Limits of Current Technologies. AAPS J. 2010, 12 (4), 708–715.

   OpenUrlPubMedGoogle Scholar
9. 9.↵
   1. Singh S. K.,
   2. Afonina N.,
   3. Awwad M.,
   4. Bechtold-Peters K.,
   5. Blue J. T.,
   6. Chou D.,
   7. Cromwell M.,
   8. Krause H.-J.,
   9. Mahler H.-C.,
   10. Meyer B. K.,
   11. Narhi L.,
   12. Nesta D. P.,
   13. Spitznagel T.

   An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics. J. Pharm. Sci. 2010, 99 (8), 3302–3321.

   OpenUrlCrossRefPubMedGoogle Scholar
10. 10.↵
    1. Burdick R.,
    2. LeBlond D.,
    3. Pfahler L.,
    4. Quiroz J.,
    5. Sidor L.,
    6. Vukovinsky K.,
    7. Zhang L.

    Statistical Applications for Chemistry, Manufacturing and Controls (CMC) in the Pharmaceutical Industry; Springer International Publishing AG, 2017.

    Google Scholar
11. 11.↵
    1. Agresti A.

    Categorical Data Analysis, 3rd ed.; John Wiley & Sons, 2013.

    Google Scholar
12. 12.↵
    1. Ramirez J. G.

    Modeling Sub-Visible Particle Data: Product Held at Accelerated Stability Conditions. Presented at the 36th Midwest Biopharmaceutical Statistics Workshop (MBSW), Muncie, IN, May 20–22, 2013.

    Google Scholar
13. 13.↵
    1. Zhang H.,
    2. Lu N.,
    3. Feng C.,
    4. Thurston S. W.,
    5. Xia Y.,
    6. Zhu L.,
    7. Tu X. M.

    On Fitting Generalized Liner Mixed-Effects Models for Binary Responses Using Different Statistical Packages. Stat. Med. 2011, 30 (20), 2562–2572.

    OpenUrlCrossRefPubMedGoogle Scholar
14. 14.↵
    1. Larsen K.,
    2. Petersen J. H.,
    3. Budtz-Jørgensen E.,
    4. Endahl L.

    Interpreting Parameters in the Logistic Regression Model with Random Effects. Biometrics 2000, 56 (3), 909–914.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
15. 15.↵
    1. Aitchison J.,
    2. Ho C. H.

    The Multivariate Poisson-Log Normal Distribution. Biometrika 1989, 76 (4), 643–653.

    OpenUrlCrossRefWeb of ScienceGoogle Scholar
16. 16.↵
    1. Cameron A. C.,
    2. Trivedi K.

    Regression Analysis of Count Data, 2nd ed.; Cambridge University Press: New York, 1998.

    Google Scholar
17. 17.↵
    1. Hedeker D.

    A Mixed-Effect Multinomial Logistic Regression Model. Stat. Med. 2003, 22 (9), 1433–1446.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
18. 18.↵
    1. Bolker B. M.

    Generalized Linear Mixed Models: A Practical Guide for Ecology and Evolution. Trends Ecol. Evol. 2009, 24 (3), 127–135.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
19. 19.↵
    1. Heiny E. L.,
    2. Frisby C. C.

    An Ordinal Logistic Regression Model for the Masters Golf Tournament. Chance 2018, 31 (3), 44–58.

    OpenUrlGoogle Scholar
20. 20.↵
    SAS Institute Inc. SAS/STAT User's Guide; SAS Institute Inc: Cary, NC, 2018.

    Google Scholar
21. 21.↵
    R Core Team. R: A Language and Environment for Statistical Computing, 2018. R Foundation for Statistical Computing Web site. http://www.R-project.org (accessed November 7, 2019).

    Google Scholar
22. 22.↵
    1. Krishnamoorthy K.,
    2. Xia Y.,
    3. Xie F.

    A Simple Approximate Procedure for Constructing Binomial and Poisson Tolerance Intervals. Commun. Stat. Theory Methods 2011, 40 (12), 2243–2258.

    OpenUrlGoogle Scholar
23. 23.↵
    1. Bates D.,
    2. Machler M.,
    3. Bolker B.,
    4. Walker S.

    Fitting Linear Mixed-Effects Models Using lme4. J. Stat. Softw. 2015, 67 (1), 1–48.

    OpenUrlCrossRefPubMedGoogle Scholar
24. 24.↵
    1. Christensen R. H. B.

    Ordinal—Regression Model for Ordinal Data. R Package Version 2019.3-9, 2019. http://www.cran.r-project.org/package=ordinal/ (accessed November 7, 2019).

    Google Scholar
25. 25.↵
    1. Young D. S.

    An R Package for Estimating Tolerance Intervals. J. Stat. Softw. 2010, 36 (5), 1–39.

    OpenUrlCrossRefPubMedGoogle Scholar